SG11202107259QA - Formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile - Google Patents

Formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile

Info

Publication number
SG11202107259QA
SG11202107259QA SG11202107259QA SG11202107259QA SG11202107259QA SG 11202107259Q A SG11202107259Q A SG 11202107259QA SG 11202107259Q A SG11202107259Q A SG 11202107259QA SG 11202107259Q A SG11202107259Q A SG 11202107259QA SG 11202107259Q A SG11202107259Q A SG 11202107259QA
Authority
SG
Singapore
Prior art keywords
quinazolin
benzonitrile
oxo
formulations
isopropyl
Prior art date
Application number
SG11202107259QA
Other languages
English (en)
Inventor
Joseph Paul Bullock
Chinmay Maheshwari
Quintus Medley
Muneto Mogi
Michela Montecchi-Palmer
Kalliopi Stasi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG11202107259QA publication Critical patent/SG11202107259QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202107259QA 2019-02-15 2020-02-13 Formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile SG11202107259QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962806705P 2019-02-15 2019-02-15
PCT/IB2020/051211 WO2020165839A1 (fr) 2019-02-15 2020-02-13 Formulations de 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile

Publications (1)

Publication Number Publication Date
SG11202107259QA true SG11202107259QA (en) 2021-08-30

Family

ID=69740424

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202107259QA SG11202107259QA (en) 2019-02-15 2020-02-13 Formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile

Country Status (20)

Country Link
US (3) US11478480B2 (fr)
EP (1) EP3923912A1 (fr)
JP (5) JP6994061B2 (fr)
KR (1) KR20210127197A (fr)
CN (2) CN117752662A (fr)
AU (2) AU2020220957B2 (fr)
BR (1) BR112021015737A2 (fr)
CA (1) CA3130237A1 (fr)
CL (1) CL2021002153A1 (fr)
CO (1) CO2021010689A2 (fr)
CR (1) CR20210428A (fr)
EC (1) ECSP21059628A (fr)
IL (1) IL284628A (fr)
JO (1) JOP20210224A1 (fr)
MX (2) MX2021009704A (fr)
PE (1) PE20212106A1 (fr)
SA (1) SA521430043B1 (fr)
SG (1) SG11202107259QA (fr)
TW (1) TWI827800B (fr)
WO (1) WO2020165839A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6994061B2 (ja) * 2019-02-15 2022-01-14 ノバルティス アーゲー 4-(7-ヒドロキシ-2-イソプロピル-4-オキソ-4h-キナゾリン-3-イル)-ベンゾニトリルの製剤
TW202045179A (zh) 2019-02-15 2020-12-16 瑞士商諾華公司 治療眼表痛之方法
TW202222298A (zh) * 2020-10-07 2022-06-16 瑞士商諾華公司 含有可溶解的眼部插入物之藥物及其使用方法
US20230159202A1 (en) * 2021-11-23 2023-05-25 Bausch + Lomb Ireland Limited Method for making a preservative-free packaged ophthalmic device product
US20240197691A1 (en) * 2022-12-15 2024-06-20 Cn2 Therapeutics, Inc. Tacrolimus compositions and methods of use
CN118340775A (zh) * 2023-01-09 2024-07-16 维眸生物科技(浙江)有限公司 一种含vvn539的眼用组合物及其用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1280874B (de) 1963-10-09 1968-10-24 Boehringer Sohn Ingelheim 2-Methyl-3-(2-dimethylaminophenyl)-8-amino-3H-chinazolon-(4)
US4027020A (en) 1974-10-29 1977-05-31 Millmaster Onyx Corporation Randomly terminated capped polymers
US3931319A (en) 1974-10-29 1976-01-06 Millmaster Onyx Corporation Capped polymers
US4407791A (en) 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US4525346A (en) 1981-09-28 1985-06-25 Alcon Laboratories, Inc. Aqueous antimicrobial ophthalmic solutions
US4836986A (en) 1984-09-28 1989-06-06 Bausch & Lomb Incorporated Disinfecting and preserving systems and methods of use
US5037647A (en) 1988-09-15 1991-08-06 Alcon Laboratories, Inc. Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride
US5145643A (en) 1990-01-05 1992-09-08 Allergan, Inc. Nonoxidative ophthalmic compositions and methods for preserving and using same
US5300287A (en) 1992-11-04 1994-04-05 Alcon Laboratories, Inc. Polymeric antimicrobials and their use in pharmaceutical compositions
BR0014203A (pt) 1999-09-24 2002-05-21 Alcon Inc Formulações de suspensão tópicas contendo ciprofloxacina e dexametasona
GB0412769D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
TWI358290B (en) 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
TWI409070B (zh) 2005-11-04 2013-09-21 Hydra Biosciences Inc 用於調節trpv3功能之化合物
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
GB0525069D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
AU2006330883A1 (en) 2005-12-22 2007-07-05 Prolexys Pharmaceuticals, Inc. 3-aryl-substituted quinazolones, and uses thereof
TW200738232A (en) 2006-01-31 2007-10-16 Alcon Mfg Ltd Use of vanilloid receptor-1 antagonists for the prevention and treatment of glaucoma
EP1964548A1 (fr) 2007-03-02 2008-09-03 Novartis AG Compositions pharmaceutiques comprenant un agent calcilytique
WO2008140750A1 (fr) 2007-05-10 2008-11-20 Hydra Biosciences Inc. Composés modulant la fonction du trp v3
AU2008277627B2 (en) 2007-07-18 2011-10-27 Novartis Ag Synergistic combinations of VR-1 antagonists and COX-2 inhibitors
TW200927192A (en) * 2007-11-19 2009-07-01 Alcon Res Ltd Use of TRPV1 receptor antagonists for treating dry eye and ocular pain
WO2009081222A1 (fr) 2007-12-21 2009-07-02 Glenmark Pharmaceuticals, S.A. Pyrimidines ou pyridines tricycliques substituées ligands des récepteurs des vanilloïdes
JP2011509296A (ja) 2008-01-09 2011-03-24 レノビス, インコーポレイテッド イオンチャネルリガンドとしてのアミド誘導体およびそれを使用する薬学的組成物および方法
WO2009090548A2 (fr) 2008-01-17 2009-07-23 Glenmark Pharmaceuticals, S.A. Dérivés de 3-azabicyclo[3.1.0]hexane utilisés comme ligands des récepteurs vanilloïdes
US8394779B2 (en) 2008-06-04 2013-03-12 Children's Medical Center Corporation Methods of modulating angiogenesis via TRPV4
WO2010023512A1 (fr) 2008-08-28 2010-03-04 Matrix Laboratories Ltd. Nouveaux modulateurs de récepteur vanilloïde, procédé pour leur préparation et compositions pharmaceutiques contenant ceux-ci
US8349852B2 (en) * 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
EP2316420B1 (fr) 2009-10-22 2014-02-26 Consorzio Universitario Unifarm Composition ophthalmique topique pour réduire la douleur
EP2377850A1 (fr) 2010-03-30 2011-10-19 Pharmeste S.r.l. Antagonistes de récepteur vanilloïde TRPV1 avec portion bicyclique
EP2627178B1 (fr) 2010-10-11 2018-05-02 Merck Sharp & Dohme Corp. Composés de type quinazolinone convenant comme antagonistes de crth2
CN102659629B (zh) * 2012-02-14 2014-03-19 杭州华东医药集团新药研究院有限公司 化合物及其在制备埃罗替尼中的用途
CN102875480A (zh) 2012-04-23 2013-01-16 中国药科大学 喹唑啉酮类血管抑制剂、其制备方法及其医药用途
GB201215857D0 (en) 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
NZ630759A (en) 2013-03-15 2017-07-28 Inotek Pharmaceuticals Corp Ophthalmic formulations comprising an a1 agonist
US20150352176A1 (en) * 2014-06-06 2015-12-10 Newport Research, Inc. Oil-free and fat-free aqueous suspensions of cyclosporin
WO2016016908A1 (fr) 2014-07-28 2016-02-04 Sun Pharma Advanced Research Company Limited Méthode d'amélioration de la biodisponibilité et/ou de prolongement de l'action ophtalmique d'un médicament
WO2016042313A1 (fr) * 2014-09-15 2016-03-24 Verona Pharma Plc Formulation liquide pour inhalation comprenant du rpl554
PL4082531T3 (pl) 2015-01-26 2024-04-08 Bausch & Lomb Incorporated Oftalmiczna kompozycja zawiesinowa
EP3515889A1 (fr) 2016-09-20 2019-07-31 GlaxoSmithKline Intellectual Property (No. 2) Limited Antagonistes de trpv4
TW201825458A (zh) 2016-09-20 2018-07-16 英商葛蘭素史克智慧財產(第二)有限公司 Trpv4拮抗劑
BR112019005416A2 (pt) 2016-09-20 2019-06-18 Glaxosmithkline Ip No 2 Ltd antagonistas de trpv4
TW202045179A (zh) * 2019-02-15 2020-12-16 瑞士商諾華公司 治療眼表痛之方法
JP6994061B2 (ja) * 2019-02-15 2022-01-14 ノバルティス アーゲー 4-(7-ヒドロキシ-2-イソプロピル-4-オキソ-4h-キナゾリン-3-イル)-ベンゾニトリルの製剤

Also Published As

Publication number Publication date
JP6994061B2 (ja) 2022-01-14
JP2022520795A (ja) 2022-04-01
CR20210428A (es) 2021-09-22
JP7465453B2 (ja) 2024-04-11
MX2021009704A (es) 2021-09-14
US11478480B2 (en) 2022-10-25
BR112021015737A2 (pt) 2021-10-26
MX2024002989A (es) 2024-03-27
US20230139170A1 (en) 2023-05-04
TWI827800B (zh) 2024-01-01
CN111568906A (zh) 2020-08-25
AU2023203933A1 (en) 2023-07-13
PE20212106A1 (es) 2021-11-04
EP3923912A1 (fr) 2021-12-22
WO2020165839A1 (fr) 2020-08-20
JOP20210224A1 (ar) 2023-01-30
JP2024037806A (ja) 2024-03-19
CL2021002153A1 (es) 2022-04-18
TW202045178A (zh) 2020-12-16
US20200390767A1 (en) 2020-12-17
WO2020165839A9 (fr) 2021-03-18
CA3130237A1 (fr) 2020-08-20
AU2020220957B2 (en) 2023-04-06
AU2020220957A1 (en) 2021-08-05
KR20210127197A (ko) 2021-10-21
US20200261457A1 (en) 2020-08-20
JP2022017260A (ja) 2022-01-25
CN111568906B (zh) 2023-09-01
CO2021010689A2 (es) 2021-08-30
JP2020132634A (ja) 2020-08-31
JP2024095674A (ja) 2024-07-10
ECSP21059628A (es) 2021-09-30
SA521430043B1 (ar) 2022-11-20
CN117752662A (zh) 2024-03-26
IL284628A (en) 2021-08-31

Similar Documents

Publication Publication Date Title
IL284628A (en) Compositions of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile
ZA201807865B (en) Formulations of an lsd1 inhibitor
IL286218A (en) Solid state forms of ripretinib
EP3509581A4 (fr) Formulations de (r
IL287224A (en) New formulations containing melphalan
IL272857A (en) Cofanalisib formulations
EP3687475A4 (fr) Stabilisation de formulations d'épinéphrine
IL290324A (en) Preparations containing tropintide
EP3810118A4 (fr) Formulations de tegavivint et composés apparentés
GB201904338D0 (en) Fluorouracil-containing formulations
IL283593A (en) Bernaflam oral preparations
PT4045038T (pt) Novas formulações de 4-cloro-n-[2-[(4-clorofenil)metil]-3-oxo-1,2,4-tiadiazol-5-il]benzamida
GB201913701D0 (en) Composition of matter
ZA202105399B (en) Use of spiropidion
IL284691A (en) formulations
IL276107A (en) Crystalline forms of psoorstam
EP3801532A4 (fr) Préparations de raltégravir
IL268632A (en) Solid formulations of amphotericin B for oral administration
PT3678644T (pt) Formulações de copanlisib
IL283005A (en) Flu drug formulations
IL310652A (en) Radiprodil formulations
IL283421A (en) Crystalline forms of Refroxlap
GB201910093D0 (en) New formulations
GB201910092D0 (en) New formulations
SG11202105114PA (en) Storage-stable form of 3-methylthiopropionaldehyde